Invo Fertility, Inc. (IVF) Stock Price & Analysis

Invo Fertility, Inc. (IVF) fell 1.96% to USD 1 as of July 25, 2026 at 03:07 UTC, according to Nexqual real-time market data.

IVF last closed at USD 1.02; the session ranged USD 1–1.04 on volume of 60,062 shares. Market capitalization is $1.79M, with a 52-week range of USD 1–94.04 (NCM). Source: Nexqual, July 25, 2026 at 03:07 UTC.

Key Statistics (as of July 25, 2026 at 03:07 UTC)

Technical Analysis (IVF)

Nexqual's technical model rates IVF "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:07 UTC.

Analyst Ratings (IVF)

Wall Street analysts rate IVF "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of July 25, 2026 at 03:07 UTC.

Earnings (IVF)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:07 UTC.

Financials & Fundamentals (IVF)

Source: Nexqual, July 25, 2026 at 03:07 UTC.

Financial Health Score (IVF)

Nexqual rates Invo Fertility, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:07 UTC.

Ownership (IVF)

Source: Nexqual, July 25, 2026 at 03:07 UTC.

Leadership (IVF)

Invo Fertility, Inc. is led by Steven M. Shum (age 54), CEO & Director, per Nexqual as of July 25, 2026 at 03:07 UTC.

Major Backers & Investors (IVF)

Notable institutional backers of Invo Fertility, Inc. include Mariner, LLC, Armistice Capital, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 03:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:07 UTC.

From Invo Fertility, Inc.'s Latest SEC 10-K Filing (filed 2026-06-02)

Key Strengths & Strategy (as disclosed to the SEC)

• These include laws that prohibit the following:     These laws are subject to extensive and increasing enforcement by numerous federal, state, and local government agencies including the Office of Inspector General, the Department of Justice, the Centers for Medicare & Medicaid Services, and various state authorities.
• The SEC allows us to disclose important information by referring to it in that manner.
• Primarily, our INVO Centers seek to employ local, reputable physicians with strong ties to the OBGYN community.   INVOcell Device   Historically, our approach to marketing INVOcell was focused on identifying partners within targeted geographic regions that we believe could best support our efforts to expand access to advanced fertility treatment using the INVOcell and IVC procedure for the large number of underserved infertile people around the world.

Partnerships

• The total purchase price was approximately $760,000, consisting of $360,000 in cash, of which $210,000 was paid at closing, and $400,000 in Series D Preferred Stock.   As part of the acquisition structure, we acquired the clinic's non-medical business assets through Wood Violet, while the clinic's medical assets were acquired by Fertility, P.A., which entered into a long-term Management Services Agreement with Wood Violet.
• On the same date, we entered into an inducement letter agreement with FNL (the "AIR Exercise and Reload Agreement"), pursuant to which FNL exercised its Additional Investment Right to acquire 1,800 shares of Series C-2 Preferred with an aggregate stated value of $1,800,000 in exchange for $1,800,000 of principal, plus accrued and unpaid interest, under the Amended and Restated Debenture.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:07 UTC. This page is informational and not investment advice.